Silence Therapeutics plc released follow-up and quality-of-life data from the Phase 1 SANRECO study of divesiran, an siRNA therapy targeting TMPRSS6, in patients with polycythemia vera. The data was presented at the European Hematology Association (EHA) 2026 Annual Congress. Silence Therapeutics plc is a biotechnology company focused on developing siRNA therapies.
